Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use
The present invention provides compositions that contain botulinum toxin and a hyaluronidase, and that lack human or recombinant serum albumin. The present invention also provides methods of administering the pharmaceutical composition to a subject in need thereof.
1 . An albumin-free composition comprising a botulinum toxin and a hyaluronidase.
2 . The composition of claim 1 , further comprising a stabilizing sugar.
3 . The composition of claim 2 , wherein said stabilizing sugar is a saccharide, disaccharide, polysaccharide or oligosaccharide.
4 . The composition of claim 3 , wherein said stabilizing sugar is trehalose, sucrose or lactose
5 . The composition of claim 1 , wherein the botulinum toxin is immunotype A, B, C, D, E, F, or G.
6 . The composition of claim 5 , wherein the botulinum toxin is botulinum toxin type A.
7 . The composition of claim 6 , wherein the botulinum toxin is from Hall strain Clostridium botulinum.
8 - 12 . (canceled)
13 . The composition of claim 1 , wherein the hyaluronidase is recombinantly produced.
14 - 17 . (canceled)
18 . The composition of claim 1 , wherein the hyaluronidase is present in an amount sufficient to stabilize the botulinum toxin.
19 - 29 . (canceled)
30 . A method for muscle denervation comprising the step of administering the composition of claim 1 to a subject in need thereof in an amount sufficient to produce local muscle denervation.
31 . A method for treating neuromuscular diseases comprising the step of administering the composition of claim 1 to a subject in need thereof in an amount sufficient to produce muscle weakness.
32 . A method for treating pain comprising the step of administering the composition of claim 1 to a subject in need thereof in an amount sufficient to reduce pain.
33 . A method for cosmetically modifying soft-tissue features comprising the step of administering the composition of claim 1 to a subject in need thereof in an amount sufficient to modify said features.
34 . A method for treating inflammation comprising the step of administering the composition of claim 1 to a subject in need thereof in an amount sufficient to reduce inflammation.
35 - 38 . (canceled)
39 . A method of treating migraine headache comprising the step of administering the pharmaceutical composition of claim 1 to a subject in need thereof, wherein administration of said formulation reduces migraine headache pain.
40 - 49 . (canceled)
50 . A method of treating tension headache comprising the step of administering the pharmaceutical composition of claim 1 to a subject in need thereof, wherein administration of said formulation reduces pain.
51 - 64 . (canceled)
65 . A method of treating depression comprising the steps of:
a) identifying a subject with a depressive disorder or identifying a subject with one or more symptoms of a depressive disorder; and
b) administering an effective amount of a composition of claim 1 to said subject thereby reducing at least one symptom of depression.
66 - 73 . (canceled)
74 . A method of treating anxiety comprising the steps of:
a) identifying a subject with an anxiety disorder or identifying a subject with at least one symptom of an anxiety disorder; and
b) administering an effective amount of a composition of claim 1 to said subject thereby reducing at least one symptom of anxiety.
75 - 102 . (canceled)
103 . A method of delivering a botulinum toxin across a blood-brain barrier, comprising the steps of identifying a subject with at least one symptom of a neuropsychiatric disorder and administering a composition of claim 1 to said subject in an amount sufficient to deliver said neurotoxin across the blood brain barrier.
104 - 170 . (canceled)
171 . A method of treating a disorder selected from the group consisting of seizures, depression, anxiety, agitation, mania, bipolar disorders, generalized seizures, mental retardation, delirium, hyperactivity syndrome, attention deficit disorder (ADD), dementia, Huntington's disease, Alzheimer's disease, Parkinson's disease, psychosis, ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig's Disease, schizophrenia, glutamate exociticity, head injury, brain hemorrhage, brain aneurysm, metabolic intoxications, insomnia, sleep disorders, comprising the step of administering to a subject in need thereof an effective amount of the composition of claim 1 .